Lamivudine耐性ウイルスに対してEntecavirを投与したB型慢性肝炎例から検出された新たなEntecavir耐性ウイルス

概要

論文の詳細を見る
Entecavir (ETV) exhibits potent antiviral activity in patients chronically infected with wild-type or lamivudine-resistant hepatitis B virus (HBV). Among the patients treated in phase II ETV clinical trials, one patient for whom previous therapies had failed exhibited virologic breakthrough while on ETV. Isolates from this patient were analyzed genotypically for emergent substitutions in HBV reverse transcriptase (RT). After 135 weeks of lamivudine therapy, patient received 0.5 mg of ETV for 52 weeks followed by 1.0 mg of ETV continuously. Viral rebound occurred at 84 weeks after ETV was started. The lamivudine RT substitutions rtH55R, rtL180M and rtM204V were present at study entry, and the additional substitutions rtS202G and rtL269I emerged during ETV treatment.
社団法人　日本肝臓学会の論文